Treating acute asthma with antibiotics - Not quite yet

New England Journal of Medicine

Volumn 354, Issue 15, 2006, Pages 1632-1634

  Little, Frédéric F ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ERYTHROMYCIN; KETOLIDE; MACROLIDE; PENICILLIN G; PLACEBO; TELITHROMYCIN; ANTIINFECTIVE AGENT;

ACUTE DISEASE; ANTIBIOTIC THERAPY; ASTHMA; BACTERIAL VIRULENCE; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; COUGHING; DISEASE EXACERBATION; DRUG FATALITY; DRUG TARGETING; EDITORIAL; HUMAN; LIVER TOXICITY; MYCOPLASMA PNEUMONIAE; NAUSEA; PRIORITY JOURNAL; SPUTUM; VIRUS INFECTION; WHEEZING; DRUG EFFECT; FORCED EXPIRATORY VOLUME; NOTE;

ANTI-BACTERIAL AGENTS; ASTHMA; FORCED EXPIRATORY VOLUME; HUMANS; KETOLIDES;

EID: 33645767962     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe068025     Document Type: Editorial

References (14)

1. Lieberman D, Lieberman D, Printz S, et al. Atypical pathogen infection in adults with acute exacerbation of bronchial asthma. Am J Respir Crit Care Med 2003;167:406-10.
2. National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma update on selected topics - 2002. J Allergy Clin Immunol 2002;110:Suppl:S141-S219. [Erratum, J Allergy Clin Immunol 2003;111:466.]
3. Johnston SL, Blasi F, Black PN, Martin RJ, Farrell DJ, Nieman RB. The effect of telithromycin in acute exacerbations of asthma. N Engl J Med 2006;354:1589-600.
4. Clay KD, Hanson JS, Pope SD, Rissmiller RW, Purdum PP III, Banks PM. Severe hepatotoxicity of telithromycin: three case reports and literature review. Ann Intern Med (in press).
5. Food and Drug Administration. Questions and answers on telithromycin (marketed as Ketek). (Accessed March 23, 2006, at http://www.fda.gov/cder/drug/ infopage/telithromycin/qa.htm.)
6. Tu D, Blaha G, Moore PB, Steitz TA. Structures of MLSBK antibiotics bound to mutated large ribosomal subunits provide a structural explanation for resistance. Cell 2005;121:257-70.
7. Center for Drug Research and Evaluation. Ketek (telithromycin): Food and Drug Administration approval documentation. (Accessed March 23, 2006, at http://www.fda.gov/cder/foi/nda/ 2004/21-144_Ketek_Microbr_P1.pdf.)
8. Camargo CA Jr, Smithline HA, Malice MP, Green SA, Reiss TF. A randomized controlled trial of intravenous montelukast in acute asthma. Am J Respir Crit Care Med 2003;167:528-33.
9. Borish LC, Nelson HS, Corren J, et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001;107:963-70.
10. Wales D, Woodhead M. The anti-inflammatory effects of macrolides. Thorax 1999;54:Suppl 2:S58-S62.
11. Schultz MJ. Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis. J Antimicrob Chemother 2004;54:21-8.
12. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002;57:212-6.
13. Amayasu H, Yoshida S, Ebana S, et al. Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Ann Allergy Asthma Immunol 2000;84:594-8.
14. Miyatake H, Taki F, Taniguchi H, Suzuki R, Takagi K, Satake T. Erythromycin reduces the severity of bronchial hyperresponsiveness in asthma. Chest 1991;99:670-3.